Allergen immunotherapy for allergic asthma: The future seems bright
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu přehledy, časopisecké články
PubMed
36702170
DOI
10.1016/j.rmed.2023.107125
PII: S0954-6111(23)00013-6
Knihovny.cz E-zdroje
- Klíčová slova
- Allergen immunotherapy, Asthma, Clinical effectiveness, Disease modification, Disease remission, Mechanisms, Prevention,
- MeSH
- alergeny MeSH
- alergická rýma * farmakoterapie MeSH
- antigeny roztočů domácího prachu terapeutické užití MeSH
- bronchiální astma * etiologie MeSH
- desenzibilizace imunologická MeSH
- lidé MeSH
- pyl MeSH
- Pyroglyphidae MeSH
- sublinguální imunoterapie * MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- alergeny MeSH
- antigeny roztočů domácího prachu MeSH
Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this mini-review, we discuss updates on new insights based on real world patient data.
Citace poskytuje Crossref.org
EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care
